Standardization and evaluation of an Anti-ZIKV IgM ELISA assay for the serological diagnosis of zika virus infection

Authors

Kanittha Sirikajornpan, Armed Forces Research Institute of Medical Sciences, Thailand
Piyarat Suntarattiwong, Queen Sirikit National Institute of Child Health
Detchvijitr Suwanpakdee, Phramongkutklao College of Medicine
Sutchana Tabprasit, Armed Forces Research Institute of Medical Sciences, Thailand
Darunee Buddhari, Armed Forces Research Institute of Medical Sciences, Thailand
Butsaya Thaisomboonsuk, Armed Forces Research Institute of Medical Sciences, Thailand
Chonticha Klungthong, Armed Forces Research Institute of Medical Sciences, Thailand
Yongyuth Poolpanichupatam, Armed Forces Research Institute of Medical Sciences, Thailand
Rome Buathong, Thailand Ministry of Public Health
Anon Srikiatkhachorn, University of Rhode Island
Anthony Jones, Armed Forces Research Institute of Medical Sciences, Thailand
Stefan Fernandez, Armed Forces Research Institute of Medical Sciences, Thailand
Taweewun Hunsawong, Armed Forces Research Institute of Medical Sciences, Thailand

Document Type

Article

Date of Original Version

10-1-2021

Abstract

Here, we describe the development of the in-house anti-Zika virus (ZIKV) IgM antibody capture ELISA (in-house ZIKV IgM ELISA) for the detection and diagnosis of acute ZIKV infections. We compared the in-house ZIKV IgM ELISA assay performance against two commercial kits, Euroimmun ZIKV IgM and InBios 2.0 ZIKV IgM ELISA. We tested the assays' ability to detect anti-ZIKV IgM using a well-defined serum sample panel. This panel included 80 ZIKV negative samples (20 negative, 20 found to be primary dengue virus [DENV][ infections, 20 secondary DENV infections, and 20 Japanese encephalitis virus [JEV] infections) and 67 ZIKV reverse transcriptase-polymerase chain reaction-positive acute serum samples. The OD values were calculated to enzyme immunoassay (EIA) unts by comparing them to weak positive controls. The results demonstrated the high sensitivity (88.06%) and specificity (90.00%) of our in-house ZIKV IgM ELISA and its 89.12% overall percentage agreement. The kappa values were deemed to be within excellent range and comparable to the InBios ZIKV IgM ELISA. Some cross-reactivity was observed among secondary DENV and JEV samples, and to a much lower extent, among primary DENV samples. These data indicate that our in-house ZIKV IgM ELISA is a reliable assay for the detection of anti-ZIKV IgM antibodies in serum.

Publication Title, e.g., Journal

American Journal of Tropical Medicine and Hygiene

Volume

105

Issue

4

Citation/Publisher Attribution

Sirikajornpan, Kanittha, Piyarat Suntarattiwong, Detchvijitr Suwanpakdee, Sutchana Tabprasit, Darunee Buddhari, Butsaya Thaisomboonsuk, Chonticha Klungthong, Yongyuth Poolpanichupatam, Rome Buathong, Anon Srikiatkhachorn, Anthony Jones, Stefan Fernandez, and Taweewun Hunsawong. "Standardization and evaluation of an Anti-ZIKV IgM ELISA assay for the serological diagnosis of zika virus infection." American Journal of Tropical Medicine and Hygiene 105, 4 (2021). doi: 10.4269/ajtmh.21-0163.